Traveler's diarrhea in Thailand: Randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 338-346

  Tribble, David R ^a   Sanders, John W ^b   Pang, Lorrin W ^f   Mason, Carl ^f   Pitarangsi, Chittima ^f   Baqar, Shahida ^a   Armstrong, Adam ^b   Hshieh, Paul ^c   Fox, Anne ^b   Maley, Elisabeth A ^d   Lebron, Carlos ^e   Faix, Dennis J ^c   Lawler, James V ^b   Nayak, Gautam ^b   Lewis, Michael ^f   Bodhidatta, Ladaporn ^f   Scott, Daniel A ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e Navy Environmental and Preventive Medicine Unit 6   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN;

ACUTE DIARRHEA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CAMPYLOBACTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEADACHE; HEAT RASH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THAILAND; TRAVELLER DIARRHEA; VAGINAL PRURITUS;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DYSENTERY; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MILITARY PERSONNEL; OFLOXACIN; SALMONELLA INFECTIONS; THAILAND;

EID: 33846405685     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510589     Document Type: Article

References (40)

1. Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165: 557-60.
2. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536-41.
3. Sanders JW, Isenbarger DW, Walz SE, et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg 2002; 67:533-8.
4. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341-5.
5. DuPont HL. Antimicrobial-resistant Campylobacter species-a new threat to travelers to Thailand. Clin Infect Dis 1995; 21:542-3.
6. Shanks GD, Smoak BL, Aleman GM, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group. Clin Infect Dis 1999; 29: 942-3.
7. Steele TW, McDermott SN. The use of membrane filters applied directly to the surface of agar plates for the isolation of Campylobacter jejuni from feces. Pathology 1984; 16:263-5.
8. Echeverria P, Sethabutr O, Serichantalergs O. Modern diagnosis (with molecular tests) of acute infectious diarrhea. Gastroenterol Clin North Am 1993; 22:661-82.
9. Echeverria P, Hoge CW, Bodhidatta L, et al. Etiology of diarrhea in a rural community in western Thailand: importance of enteric viruses and enterovirulent Escherichia coli. J Infect Dis 1994; 169:916-9.
10. Jiang X, Wilton N, Zhong WM, et al. Diagnosis of human caliciviruses by use of enzyme immunoassays. J Infect Dis 2000; 181 (Suppl 2): S349-59.
11. Huang MB, Baker CN, Banerjee S, Tenover FC. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol 1992; 30:3243-8.
12. NCCLS. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. M100-S8. Vol 18. Wayne, PA: NCCLS, 2002.
13. National antimicrobial resistance monitoring system (NARMS): enteric bacteria 2000 annual report. Atlanta: Centers for Disease Control and Prevention, 2000.
14. DuPont HL, Cooperstock M, Corrado ML, Fekety R, Murray DM. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(Suppl 1):S228-35.
15. Trabulsi LR, Keller R, Tardelli Gomes TA. Typical and atypical enteropathogenic Escherichia coli. Emerg Infect Dis 2002; 8:508-13.
16. Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994; 38:1915-21.
17. Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997; 61:641-8.
18. Treadway G, Pontani D, Reisman A. The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. Int J Antimicrob Agents 2002; 19:189-94.
19. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37:1165-71.
20. Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, de la Cabada FJ. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea: a placebo-controlled, randomized trial. Ann Intern Med 1987; 106:216-20.
21. Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone: a placebo-controlled, randomized trial. Ann Intern Med 1991; 114:731-4.
22. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706-9.
23. Adler-Mosca H, Luthy-Hottenstein J, Martinetti Lucchini G, Burnens A, Altwegg M. Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991; 10:953-7.
24. Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996; 22:1019-25.
25. Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 1992; 117:202-8.
26. Inagaki Y, Horiuchi S, Une T, Nakaya R. In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea. J Antimicrob Chemother 1989; 24:547-9.
27. Silley P. Campylobacter and fluoroquinolones: a bias data set? Environ Microbiol 2003; 5:219-30.
28. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 1995; 41: 48-81.
29. Sack RB, Santosham M, Froehlich JL, Medina C, Orskov F, Orskov I. Doxycycline prophylaxis of travelers' diarrhea in Honduras, an area where resistance to doxycycline is common among enterotoxigenic Escherichia coli. Am J Trop Med Hyg 1984; 33:460-6.
30. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 1990; 43:608-13.
31. Pitkanen T, Pettersson T, Pomka A, Kosunen TU. Effect of erythromycin on the fecal excretion of Campylobacter fetus subspecies jejuni. J Infect Dis 1982; 145:128.
32. Richardson JF, Frost JA, Kramer JM, et al. Coinfection with Campylobacter species: an epidemiological problem? J Appl Microbiol 2001; 91:206-11.
33. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7:24-34.
34. Murphy GS Jr, Echeverria P, Jackson LR, Arness MK, LeBron C, Pitarangsi C. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996; 22:868-9.
35. Isenbarger DW, Hoge CW, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002; 8:175-80.
36. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001;45:212-6.
37. Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 2001; 7:996-1003.
38. Hakanen A, Jousimies-Somer H, Siitonen A, Huovinen P, Kotilainen P. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003; 9:267-70.
39. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002; 8:1501-3.
40. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-15.